Kaleido Biosciences Prices $75M IPO Below Range
By Darcy Reddan ( February 28, 2019, 2:19 PM EST) -- Clinical-stage biotech company Kaleido Biosciences said late Wednesday that it has priced a $75 million initial public offering that was steered by Goodwin Procter LLP below the expected price range....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.